The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
02-Mar-98
$400 million
Target:
Olsy SpA (Olivetti SpA)
Acquiror:
Wang Laboratories Inc.
Advised Wang on its acquisition of Olsy, the systems and solutions division of Olivetti, for a combination of cash and securities.
16-Jul-98
$1.5 billion
Target:
iMCI
Acquiror:
Cable and Wireless plc
, MCI’s Internet Business
Advised C&W on the financing of its iMCI acquisition via the largest equity primary placement to date in the London market
30-Jul-01
$117 million
Target:
Kymata Ltd.
Acquiror:
Alcatel Optronics
Advised Kymata Ltd, the Scottish manufacturer of optical components, on its sale to Alcatel Optronics of France.
29-Aug-02
$6.2 billion
Target:
Marconi plc
Advised the official committee of bondholders of Marconi, a leading telecom equipment provider, on the financial restructuring of Marconi's £4 billion of externally held financial indebtedness
18-Jul-05
$101 million
Target:
TeleCity Plc
Acquiror:
Inhoco 3236 plc (joint venture between 3i and Oak Hill Capital)
Advised TeleCity plc on the recommended offer by 3i and Oak Hill Capital
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
08-Aug-06
$565 million
Target:
Emdeon Practice Services, Inc.
Acquiror:
The Sage Group plc
Advised The Sage Group plc, a leading international supplier of accounting and business management software solutions
19-Dec-06
$270 million
Target:
Brion Technologies, Inc.
Acquiror:
ASML Holding N.V.
Advised ASML Holding N.V., a leading provider of lithography systems for the semiconductor industry, on its acquisition of Brion Technologies, Inc.
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
05-Aug-08
$NA
Target:
BARTEC Group
Acquiror:
Capvis
Advised Capvis, a leading Swiss private equity firm, on its acquisition of the BARTEC Group, a leading European provider of industrial safety technology, from Allianz Capital Partners, the captive private equity arm of Allianz AG, and the Barlian family (founding family)
15-Sep-08
$189 million
Target:
Fermat International
Acquiror:
Moody’s Corporation
Advised Moody’s Corporation on its acquisition of Fermat International, a leading provider of risk and performance management software to the global banking sector
01-Oct-08
$53 million
Target:
Biotage (Biosystems division)
Acquiror:
Qiagen NV
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
01-May-09
$65 million
Target:
euNetworks Group Limited
Advised euNetworks Group Ltd, a Singapore listed operator of a fibre telecommunications network in Europe, on a repurchase at a discount of the majority of its outstanding convertible bonds, financed by a placement and rights issue
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
04-Dec-09
$NA
Target:
Verivox Holding Limited
Acquiror:
Oakley Capital Private Equity LP
Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity
12-May-10
$NA
Target:
Experian plc
Acquiror:
British Sky Broadcasting Group plc
Advised Experian plc, the FTSE100 global information services company, on the sale of certain UK database marketing activities into a newly formed joint venture with British Sky Broadcasting Group PLC
04-Jun-10
$232 million
Target:
Manx Telecom
Acquiror:
HgCapital
Advised HgCapital, a leading European private equity investor, on its acquisition of Manx Telecom, the Isle of Man's main telecommunications and internet provider and a subsidiary of Telefónica S.A.
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
24-Sep-10
$371 million
Target:
Intec Telecom Systems plc
Acquiror:
CSG Systems
Advised CSG Systems, a leading provider of customer management and billing solutions in North America, on its acquisition of Intec Telecom Systems plc, a global provider of BSS solutions
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
13-Dec-10
$256 million
Target:
Maxinutrition Group Holdings Limited
Acquiror:
GlaxoSmithKline Plc
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
09-Jul-12
$4.7 billion
Target:
ASML Holding NV (minority stake)
Acquiror:
Customers including Intel Corporation, TSMC and Samsung Electronics
Advised the Supervisory Board of ASML on the establishment of a Customer Co-Investment Program including the issue of 23% equity stake and $1.7 billion of R&D funding
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa